Ted Davis, a 25-year veteran of the life science industry, has been appointed president and chief executive officer of Active Implants LLC, a company headquartered in Memphis, Tennessee. Davis succeeds Henry Klyce, who will continue as chairman of the board.
According to the February 22, 2017 news release, “…Davis has 25 years of experience in the life sciences industry as an investor and senior executive, including chief executive officer of MicroPort Orthopedics and president of its predecessor Wright Medical Technology’s global OrthoRecon division from 2012 through 2015. Prior to leading the carve out and integration of the OrthoRecon platform, Davis led Wright’s business development, corporate development and research & development functions from 2006 to 2012, with increasing responsibility for the business development, government affairs, national accounts, reimbursement, medical education and global research & development teams.”
“Davis oversaw the acquisition and integration of a series of extremities and biologics platforms during Wright’s transformation into the market leader in the extremities market segment. Prior to joining Wright in 2006, Davis spent 10 years in the life sciences venture capital field, serving on the boards of multiple biotechnology and medical device companies while at MB Venture Partners and Vector Fund Management. He holds an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree in engineering from Vanderbilt University.”
Davis told OTW, “Having been a member of the Board for the past year, my priorities will be to continue the projects Henry and the team have in motion including accelerating the transition from a development-stage company to a commercial-stage company. We will focus on completing the enrollment of our two clinical trials for the NUsurface here in the U.S. and our limited commercial release in Europe. Additionally, in the current healthcare market environment, clinical and economic justification have become critical to the commercial success for any new device, so we will be increasing our investment in these efforts as our clinical data matures.”
